The World Health Organization (WHO) has made one new and one renewed appointment to its executive board: Zsuzsanna Jakab has been named WHO regional director for Europe, while Dr Luis Gomes Sambo has been re-appointed WHO regional director for Africa. Mrs Jakab, who was previously director of the European Centre for Disease Prevention and Control, succeeds Dr Marc Danzon, who has served as European regional director for the past 10 years. Dr Sambo first took the role as regional director for Africa in 2005; before that he held a number of health-based roles in Angola, including vice-minister of health, director of health service in the Cabinda province and director of international co-operation at the ministry of health in Luanda.
WHO makes new executive board appointments
Listen to this article
The World Health Organization (WHO) has made one new and one renewed appointment to its executive board: Zsuzsanna Jakab has been named WHO regional director for Europe, while Dr Luis Gomes Sambo has been re-appointed WHO regional director for Africa. Mrs Jakab, who was previously director of the European Centre for Disease Prevention and Control, succeeds Dr Marc Danzon, who has served as European regional director for the past 10 years. Dr Sambo first took the role as regional director for Africa in 2005; before that he held a number of health-based roles in Angola, including vice-minister of health, director of health service in the Cabinda province and director of international co-operation at the ministry of health in Luanda.
Keep up with the top pharma business news of the week. On the go.
More from Business
• By
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
• By
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains